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Abstract
Objective and Methods: A long-term observational study was conducted in Samara, Russia to assess the survival and risk
factors for death of a cohort of non-multidrug resistant tuberculosis (non-MDRTB) and multidrug resistant tuberculosis
(MDRTB) civilian and prison patients and a civilian extensive drug-resistant tuberculosis (XDRTB) cohort.
Results: MDRTB and XDRTB rates of 54.8% and 11.1% were identified in the region. Half (50%) of MDRTB patients and the
majority of non-MDRTB patients (71%) were still alive at 5 years. Over half (58%) of the patients died within two years of
establishing a diagnosis of XDRTB. In the multivariate analysis, retreatment (HR= 1.61, 95%CI 1.04, 2.49) and MDRTB
(HR= 1.67, 95%CI 1.17, 2.39) were significantly associated with death within the non-MDR/MDRTB cohort. The effect of age
on survival was relatively small (HR = 1.01, 95%CI 1.00, 1.02). No specific factor affected survival of XDRTB patients although
median survival time for HIV-infected versus HIV-negative patients from this group was shorter (185 versus 496 days). The
majority of MDRTB and XDRTB strains (84% and 92% respectively) strains belonged to the Beijing family. Mutations in the
rpoB (codon 531 in 81/92; 88.8%), katG (mutation S315T in 91/92, 98.9%) and inhA genes accounted for most rifampin and
isoniazid resistance respectively, mutations in the QRDR region of gyrA for most fluroquinolone resistance (68/92; 73.5%).
Conclusions: Alarmingly high rates of XDRTB exist. Previous TB treatment cycles and MDR were significant risk factors for
mortality. XDRTB patients’ survival is short especially for HIV-infected patients. Beijing family strains comprise the majority of
drug-resistant strains.
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Introduction
Multidrug-resistant tuberculosis (MDRTB) is a growing threat
to national tuberculosis (TB) programmes world-wide. Extensive
drug-resistance (XDR), i.e. additional resistance to fluoroquino-
lones (FQ) and injectable agents decreases chances of survival and
success further [1,2,3,4,5,6,7]. So far co-infection of HIV and
XDRTB has been largely fatal [2,8,9,10,11].
The problem of drug–resistant tuberculosis is particularly acute
in the countries of the Former Soviet Union (FSU) where almost
half of all TB cases are resistant to at least one drug and the
MDRTB rate among new cases exceed 20% in some countries
[12]. The extent and pattern of resistance to second-line drugs
(SLD) among MDRTB isolates remain unknown in most FSU
countries due to insufficient laboratory infrastructure and testing.
Only limited data is available on patient survival in the long term
and where reported in Russia, cure rates and short-term survival
have been poor regardless of HIV status [13,14].
In Samara Oblast (a region of the Russian Federation with a
population of 3.3 million) high rates of MDRTB (20% among new
and 43% among previously treated cases) are coupled with a fast
growing HIV epidemic (HIV-positive cases reaching 43 000 in
December 2010) [15,16]. A drug-resistance survey conducted in
2001–2002 in this region demonstrated relatively low rates of
resistance to second-line drugs with no XDRTB cases [17].
Prolonged hospitalization (minimum 3 months) is compulsory for
culture-confirmed patients; HIV-infected patients stay at the same
hospitals with other patients including drug-resistant cases.
Institutional infection control measures are not fully implemented,
i.e. there are no negative-pressure rooms, appropriate protective
masks are not worn regularly by staff, there is no strict separation
of in-patients with sensitive and resistant tuberculosis and there are
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opportunities for patients to meet socially. The potential for HIV
infected patients to become infected with drug resistant TB is high.
The aim of this study was to determine the long-term survival of
drug-sensitive (non-MDR), MDRTB and XDRTB patients in the
civilian and prison sectors, and to identify risk factors including TB
strain type, associated with survival.
Materials and Methods
Ethics statement
The study was approved by Samara Medical University Ethics
Committee and received a waiver of informed consent.
Study settings and population
Results of two independent patient cohorts from the same
region of Russia are presented. Patients from a non-MDR/
MDRTB Cohort (N= 880) were prospectively consecutively
recruited from the civilian and prison sectors into the study in
2002–2003 within a pilot DOTS-programme; this ‘‘2002-3 TB
Cohort’’ was comprised of new (88%) and relapse cases infected
with MDRTB and non-MDR strains (including fully-sensitive and
mono-/polyresistant) and was followed prospectively until De-
cember, 31st 2008 to give long-term survival data.
XDRTB Cohort consisted of all civilian patients diagnosed with
XDRTB in the same region in 2008 (‘‘2008 XDRTB Cohort’’).
All identified XDRTB patients were enrolled into the analysis
(n = 92). Basic data on history of TB and survival were collected
using routine TB patients’ register supplemented with detailed
epidemiological and clinical data from chart review.
Bacteriological methods
For all patients, smear microscopy was performed using the
Ziehl-Neilsen method with culture on Lowenstein-Jensen media
according to standard procedures [18]. Overall, mycobacterial
isolates were obtained from 783 patients in the 2002-3 Cohort.
First-line drug susceptibility testing (FLD DST) was performed
using either conventional solid media (by the absolute concentra-
tion method), or the MGIT 960 system using standard techniques
[18,19]; second line DST was performed using the MGIT system
as described [20,21]. Drug concentrations used for second-line
drugs were (mg/ml): Ofloxacin (Ofl): 2.0; Moxifloxacin (Mox):
0.25; Amikacin (Amk): 1.0; Capreomycin (Cap): 2.5; Prothiona-
mide (Pt): 2.5 [20].
Prior to routine implementation of SLD MGIT 960 testing,
laboratory staff were trained, and the methodology quality
controlled and validated by the UK Health Protection Agency
National Mycobacterium Reference Laboratory (HPA NMRL);
for quality control purposes 31 isolates were randomly selected
and re-tested additionally for FLD and SLD drugs with complete
concordance at the NMRL.
Molecular genotyping methods
Detection of mutations in genes associated with resistance to
rifampin and isoniazid was performed on all isolates from both
Cohorts using an in-house reverse hybridization assay [22,23,24]
capable of detecting the most common mutations in genes katG,
inhA, and rpoB.
Identification of mutations associated with the FQ resistance
was performed for all XDRTB isolates at the NMRL by
sequencing the quinolone-resistance-determining region (QRDR)
of the gyrA gene (codons 88–100) using a pyrosequencing assay
(Qiagen, Hilden, Germany). Genetic families were identified by
spoligotyping for both Cohorts [25]. XDRTB isolates were also
genotyped at the Samara Oblast Dispensary Laboratory and at the
NMRL, London using Variable Number Tandem Repeat
(VNTR) typing with 15 MIRU loci [26] and an additional panel
of 13 highly discriminatory loci [27,28]. PCR fragments were
separated and sized manually (in Samara) and by using automated
capillary electrophoresis in London (CEQ8000 Genetic Analysis
System, Beckman Coulter) as described previously [25].
Main outcome measures
All cases within both Cohorts were included in the descriptive
analysis.
The study endpoint was time to death, calculated since TB
diagnosis in the 2002-3 TB Cohort patients and from XDRTB
identification in the 2008 XDRTB Cohort patients. Survival time
was the difference between the diagnosis and death dates. Cases
who died before therapy started from the 2002-3 TB Cohort
(n = 3) were not included. Cases who were alive were censored: for
the 2002-3 TB Cohort-at 31st of December 2008, for the 2008
XDRTB Cohort- at 31st of December 2009.
In the 2002-3 TB Cohort potential predictors of survival
collected were: gender, age, residence (civilian, prisoner), infection
type (new, relapse), HIV status (negative, positive), strain family
(Beijing, non-Beijing) and resistance (MDRTB, non-MDRTB). A
proportion of patients (n = 97) which were not culture-confirmed
(diagnosis was based on clinical/radiological presentation) were
excluded from the analysis of the effect of drug-resistance and
strain type on survival.
In the 2008 XDRTB Cohort potential predictors of survival
collected were: gender, age, residence (civilian, prisoner), infection
type (new, re-treatment), HIV status (negative, positive), extent of
lung damage (number of lung zones affected and presence of
cavities), clinical symptoms (cough, shortness of breath (SOB),
fever, weight loss, chest pain, haemoptysis), strain family (Beijing,
non-Beijing), adherence to treatment and alcohol/drug abuse.
Although recruitment occurred in the same settings, the two
groups were analysed independently to avoid bias that may result
from combining them.
Statistical analysis
All data was entered on a password protected stand-alone
database to maintain confidentiality.
Statistical analysis was carried out separately for both Cohorts
using STATA 10.0 (Stata-Corp, TX, USA).
The x2-test was used to compare proportions. Tests of significance
were 2-sided, and P=0.05 was considered statistically significant.
Survival data was summarised using Kaplan-Meier graphs. Univar-
iate analysis using Cox’s proportional hazards model was performed
for each potential predictor. Those which were significantly
associated with increased risk of death at the 10% significance level
were fitted together in a multivariate model. Analysis was performed
on the available case sample (i.e. that each analysis only included
participants where all their information required for that analysis was
present). If a participant was lost to follow up they were censored at
the last time they were known to have been alive.
The variables included in the final model were checked for the
assumption of proportional hazards and the proportional hazards
assumption was not violated (data not shown).
Statistical analysis was conducted by an author independent of
the recruitment or laboratory sites.
Results
Rate of MDRTB and XDRTB in population
From a comprehensive analysis, in 2008 of 2048 individual
patients (from consecutive patients at all 36 clinics) an overall rate
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of MDRTB of 54.8% (1123/2048) was obtained; SLD was
performed on, and readable results obtained from 1025/1123
(91.3%) MDRTB isolates, and 114 XDRTB (11.1%) isolates were
identified. In 2002-3 TB Cohort the rate of MDRTB was 17.5%
among new patients and 34.0% among relapse cases [29].
Clinical and demographic characteristics
The main clinical and demographic characteristics of both
Cohorts are given in Table 1.
The majority of patients from the 2002-3 TB Cohort came from
the civilian sector, and 19% were prisoners at the time of the
study. All patients from this Cohort and the majority of the 2008
XDRTB Cohort patients (96%) were tested for HIV at the point of
TB diagnosis; the HIV-positivity rate was higher in the 2008
XDRTB Cohort compared to the 2002-3 TB Cohort patients (9%
vs. 4%). None of the HIV-positive patients was receiving highly
active antiretroviral treatment (HAART) at the time of the study.
More detailed clinical information was available for the 2008
XDRTB Cohort patients. Approximately half of the XDRTB
patients were symptomatic with a productive cough being the most
common complaint. SOB (39%), fever (24%) and weight loss
(13%) were relatively common but chest pain (13%) and
haemoptysis (7%) were rare.
The majority of the 2008 XDRTB Cohort patients had
extensive lung damage with more than one segment affected (in
70% of patients) and the presence of cavities in 93% of patients.
Almost all patients from this Cohort were smokers (81%); 25% and
46% of them abused alcohol and recreational drugs. Almost all
2008 XDRTB Cohort patients (98%) were hospitalised for
treatment. Many patients (44%) were not adherent to anti-
tuberculosis therapy and frequent interruptions (for # and $1
months (but less than 2 months for qualify for ‘‘default’’) as well as
general poor compliance were reported by attending physicians.
By the end of the follow-up period, 24% of patients in the 2002-
3 TB Cohort and 58% in the 2008 XDRTB Cohort had died
(Table 1).
Molecular drug resistance patterns and epidemiology of
MDR and XDRTB strains
2002-3 TB Cohort: all available isolates (536/783; 68%) were
genotyped; a smaller proportion of strains belonged to the Beijing
family among non-MDRTB isolates than for MDRTB isolates
where the Beijing family dominated (84% versus 16%; RR 5.1;
95%CI 3.2, 8.2).
2008 XDRTB Cohort: mutations in katG and inhA genes
associated with isoniazid resistance were detected in 91/92
(98.9%) strains and ninety strains (97.8%) had rpoB gene mutations
with excellent agreement between molecular and phenotypical
DST results (98.9%). Most rifampin-resistant strains had poly-
morphisms in codon 531 (81 strains, 88.0%). In isoniazid-resistant
isolates, 91 harboured the S315T mutation in the katG gene which
was combined with the mutation C(215)T in the inhA gene in 11
isolates (11.9%).
Sequencing analysis to detect key mutations associated with
fluroquinolone resistance was performed on all 92 isolates from the
2008 XDRTB Cohort. Mutations in the QRDR region of the gyrA
gene were found in 68 (73.9%) isolates with mutations at codon 94
GACRGGC (D94G) being the most prevalent (57.4%). Other
Table 1. Core common clinical and demographic characteristics of patients from the 2002-3 TB Cohort and 2008 XDRTB Cohort*.
Characteristic, no.(%) Categories 2002-3 TB Cohort
2008 XDRTB
Cohort
DST not performed
N=97 MDR N=139 Non-MDR N=644 Total N=880 XDR N=92
Gender Male 97 (100%) 119 (86%) 493 (77%) 709 (81%) 68 (74 %)
Female 0 (0%) 20 (14%) 151 (23%) 171 (19%) 24 (26%)
Age #40 y.o. 85 (88%) 80 (58%) 321 (50%) 486 (55%) 45 (49%)
.40 y.o. 12 (12%) 59 (42%) 323 (50%) 394 (45%) 47 (51%)
Imprisonment Civilian 0 (0%) 106 (76%) 610 (95%) 716 (81%) 92 100%)
Prisoner 97 (100%) 33 (24%) 34 (5%) 164 (19%) 0
Treatment history New 91 (94%) 122 (88%) 590 (92%) 803 (92%) 5 (6%)
Re-treatment 6 (6%) 17 (12%) 52 (8%) 75 (9%) 85 (94%)
Total 97 139 642 878 90
HIV Status Negative 84 (87%) 133 (96%) 625 (97%) 842 (96%) 80 (91%)
Positive 13 (13%) 6 (4%) 19 (3%) 38 (4%) 8 (9%)
Total 97 139 644 880 88
Strain family Beijing - 77 (84%) 193 (43%) 270 (50%) 85 (92%)
Other - 15 (16%) 251 (57%) 266 (50%) 7 (8%)
Total - 92 444 536 92
Survival status
Alive 80 (82%) 98 (71%) 490 (76%) 668 (76%) 39 (42%)
Dead 17 (18%) 41 (30%) 154 (24%) 212 (24%) 53 (58%)
Follow up time
median (IQR)
4.2 years (2.82, 4.81) 2.6 years (1.62, 3.68) 3.8 years (2.53, 4.49) 3.7 years (2.33, 4.46) 1.3 years (0.5, 1.5)
*Note: 3 people do not contribute any survival time data.
doi:10.1371/journal.pone.0020531.t001
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mutations included A90V (16.2%), D94A (16.2%), D94N (4.4%),
D94Y (3.0%), and G88A (1.5%). Naturally occurring polymor-
phisms in codon 95 (AGC-ACC) not associated with resistance to
FQ was seen in all but two strains (both belonging to the T1
family) (Table 2).
VNTR typing demonstrated that the majority of XDRTB
strains (85/92, i.e. 92%) belonged to the Beijing family; other
identified families included Haarlem 3 (3 isolates), Family 33 (1),
T1 (2), and T4 (1). We showed high clonality of XDRTB strains in
Samara with a small number of dominant strains (Table 2).
Long-term survival and factors associated with survival
2002-3 TB Cohort. Half (50%) of MDRTB patients and the
majority of non-MDR patients (71%) were still alive at 5 years
(Figure 1A).
In a univariate Cox regression model for patients from this
Cohort (Table 3), survival was significantly associated with being
male, older age, MDRTB status, HIV co-infection and being a
relapse case. Prisoners were no more likely to die than civilians
(HR 1.04; 95% CI 0.75, 1.45). Infection with Beijing family strains
had no effect on survival (HR 0.78; 95%CI 0.54, 1.11).
In the multivariate model containing all factors of significance
only relapse/past treatment and multi-drug resistance remained
associated with lower survival (HR 1.61; 95%CI 1.04, 2.49 and
HR 1.67, 95%CI 1.17, 2.39 respectively).
Although older age was significantly associated with increased
mortality, the effect was relatively small, i.e. per each year increase
in age (HR 1.01; 95%CI 1.00, 1.02) (Table 3).
HIV status did not affect survival of patients from the 2002-3
TB Cohort (as overall this Cohort contains predominantly new
drug-sensitive TB cases) with comparable survival for patients who
were HIV-infected (79% were alive) versus HIV-negative (69%
were alive) at 5 years after diagnosis supporting data from other
countries that treatment for drug sensitive TB was as effective for
HIV positive patients as HIV negative at the early stages of
immunodeficiency [30].
2008 XDRTB Cohort. Over half (58%) of the patients died
within two years of establishing a diagnosis of XDRTB (Figure 1B).
For XDRTB patients none of the factors reached statistical
significance for survival in a univariate Cox regression model including
HIV co-infection (HR 1.23; 95%CI 0.49, 3.11): age, gender, treatment
history, or strain family (Table 3). However, median survival time for
HIV-infected patients with XDRTB was only 185 days (0.5 years)
compared to 496 days (1.4 years) for HIV negative participants.
Additionally analysed clinical factors (presence of cough,
haemoptysis, SOB, chest pain, weight loss, fever, cavitations,
involvement of multiple lung zones, smoking, alcohol and drug
abuse, hospitalisation and adherence to therapy) did not appear to
affect survival.
Discussion
Our drug resistance survey conducted earlier in Samara Oblast
provided hope for development of a standardized MDRTB
treatment regimen with a successful treatment outcome. This
follow-up analysis conducted six years later in the same
geographical settings showed alarmingly high rates of XDRTB
(11.1%) against the background of a rapidly evolving epidemic of
HIV.
Molecular genotyping analysis demonstrated that the over-
whelming majority of MDRTB/XDRTB (84% and 92%
respectively) isolates belonged to the Beijing TB strain family that
is substantially higher than was detected through the earlier study
(2001–2002) in the same region (62% of those MDRTB strains
belonged to the Beijing strain) [24]. In non-MDRTB strains the
proportion of isolates from the Beijing strain family was
significantly lower. Circulating strains were extremely homoge-
neous with the majority of XDRTB cases associated with two
main clones in Samara. Detailed molecular epidemiological
mapping to detect factors facilitating such successful spread of
this family strain across Eastern Europe is currently under way.
Factors contributing to drug-resistance development, such as poor
adherence to therapy and absence of social support as well as of
treatment incentives/motivation, frequent treatment interruption
and inadequate therapeutic regimens without reliable SLD DST
results, have been described previously for Russian settings
[6,24,31,32,33]. Now despite the initiation of international TB
control projects the consequences of relatively low cure rates,
limited infection control, increasing availability and use of the
second-line drugs for both TB and no-TB infections, and their
availability without prescription [34,35] can be seen.
Previous TB treatment cycles and MDRTB and XDRTB were
significant risk factors for mortality. Although not reaching
statistical significance overall (possibly due to a relatively small
number of HIV-positive cases among the overall group) HIV co-
infection did result in higher mortality rates confirming data from
other studies [36,37,38]. The rate of HIV co-infection which was
4% in 2003 almost doubled, reaching 9% in 2008 showing an
Table 2. XDR strains molecular genotypes and proportions of common mutations associated with fluroquinolone resistance.
Cluster No.*
VNTR profile**
(MIRU2,4,10,16,20,23,24,26,27,31,39,40,
ETR-A, -B, -C, VNTR424, 1955, 1982,
2347, 2401, 3171, 3232, 3336, 3690,
4052, 4156, 2163A, 2163B) Mutations in the gyrA gene, no.(%)
90 GTG 94 AAC 94 GGC 94 GCC 94 TAC 88 GCC Wild type
1 (N=36) 223325153533424448443(12)726296 4 (11.1%) 3 (8.3%) 15 (41.7%) 4 (11.1%) 1 (2.8%) 0 9 (25.0%)
2 (N=15) 223325173533424446443(14)727296 3 (20.0%) 0 6 (40.0%) 1 (6.7%) 1 (6.7%) 0 4 (26.7%)
3 (N=3) 223325153533424448443(14)728296 1 (33.3%) 0 2 (66.6%) 0 0 0 0
4 (N=3) 223325173533424446443(14)722296 0 0 1 (33.3%) 2 (66.6%) 0 0 0
5 (N=3) 223325153533424448443(15)728296 0 0 0 1 (33.3%) 0 0 2 (66.6%)
6 (N=3) 223325173533424446443(12)722296 1 (33.3%) 0 1 (33.3%) 1 (33.3%) 0 0 0
*Clusters were identified using VNTR and spoligotyping.
**The VNTR types are given as 28-digit codes corresponding to the numbers of copies of minisatellites in respective loci (please see column heading).
doi:10.1371/journal.pone.0020531.t002
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alarming trend in the convergence of the two epidemics in the
region. Recent preliminary analysis for 2010 has suggested that the
rate of TB-HIV co-infection has increased further reaching 16%
(data not shown).
Nevertheless long-term survival of MDRTB patients was better
than reported previously with half of MDRTB patients alive 5
years after diagnosis. However, XDRTB killed more than half of
patients in less than 18 months. Prisoners and civilians with
MDRTB had a similar mortality. Although providing hope, this
also means that many chronically ill patients survive relatively long
periods of time and undergo numerous repetitive cycles of
empirical treatment including prolonged hospitalizations and
subsequent contact with HIV-infected individuals. In these
circumstances, introduction of rapid and reliable molecular
screening methods for MDRTB and XDRTB would be of value
so that MDRTB/XDRTB patients can be segregated early to
interrupt transmission and to initiate treatment promptly. The
combined use of traditional phenotypical and molecular ap-
proaches allows both accurate and fast laboratory screening and
testing of sensitivities to the second-line drugs [7], and appropriate
initiation of infection control measures and therapy. Where this
has occurred successfully, e.g., Peru, survival has improved [39].
The study had some limitations. We were not able to obtain full
clinical and epidemiological information for all patients, e.g.,
information about treatment regimens was not included into
analysis of survival but treatment for patients follows Russian
Federal regulations which for MDRTB and XDRTB patients
involve therapy tailored to individual drug susceptibility results
[18]. Nevertheless delays in establishing effective treatment were
and remain common. Due to differences between patients’ groups,
a direct comparison of survival of MDRTB and XDRTB patients
was not conducted. Although the current study represents a
Figure 1. Kaplan-Meier survival curves for patients from (A) 2002-3 TB Cohort defined by MDR- vs non-MDR status and (B) 2008
XDRTB Cohort.
doi:10.1371/journal.pone.0020531.g001
Survival of MDR/XDRTB Patients in Russia
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20531
heterogeneous population, it provides the first evidence of the
extent and the pattern of XDRTB and the evolution of significant
rates of HIV co-infection in Samara Oblast as well as describes the
chances of long-term survival of civilian and prison patients
infected with MDRTB /XDRTB strains with and without HIV
co-infection. This study is one of the largest in terms of the cohorts’
size and length of follow-up.
As Samara Oblast represents a typical setting in the Russian
Federation and in many other FSU countries, the data can be
generalized country- and region-wide.
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*Three people died on the same date as diagnosis and hence do not contribute any time to the analysis.
**In the multivariate Cox model age was taken as a continuous variable.
‘Patients without available DST results from 2002-3 TB Cohort are excluded from the analysis.
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